Contribute Try STAT+ Today

The growing number of drug shortages plaguing the U.S. health care system is due to what federal officials are calling a “broken marketplace.” And they contend the problem might be fixed with a better understanding of the effect on patients, as well as new incentives for companies to invest in high quality manufacturing facilities.

In a new report, the Food and Drug Administration noted that the number of ongoing shortages has been steadily rising — reaching about 110 — after peaking in 2011 and then declining until last year. Moreover, the agency analyzed 163 drugs for which shortages existed and found that most were relatively lower priced and financially unattractive for manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.